China Oncology ›› 2017, Vol. 27 ›› Issue (11): 913-916.doi: 10.19401/j.cnki.1007-3639.2017.11.013

Previous Articles     Next Articles

The resistance mechanism and coping strategy of the third-generation EGFR-TKIs in NSCLC

QIN Shanshan, CHANG Jianhua   

  1. Department of Medical Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
  • Online:2017-11-30 Published:2017-12-12
  • Contact: CHANG Jianhua E-mail:

Abstract: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) targeted therapy has great advantages compared to conventional chemotherapies and has become the first-line treatment of EGFR sensitive mutations in patients with advanced non-small cell lung cancer. However, the development of acquired drug resistance is inevitable. EGFR T790M mutation is the main mechanism of the first and second generation EGFR-TKIs. The thirdgeneration EGFR-TKIs including AZD9291 and CO-1686 showed favorable treatment effect in clinical trials. However, resistance problems appeared soon. This review summarized the resistance mechanisms of the third-generation EGFRTKIs and the potential coping strategy.

Key words: Epidermal growth factor receptor, Non-small cell lung cancer, The third-generation epidermal growth factor receptor tyrosine kinase inhibitors, Resistance mechanism